FDAnews Announces — New Trump Administration, New Republican Congress: What Will the FDA’s Agenda Be in 2017? Webinar, Dec. 15, 2016

Share Article

What is coming for the FDA and its regulated industries? Steve Grossmann, a long-time D.C. insider, who served as a Senate Health Committee Staff Director and Deputy Assistant Secretary of Health, will discuss what the FDA is doing today and what it likely will be doing under the next administration.

FDAnews

FDAnews

New Trump Administration, New Republican Congress:
What Will the FDA’s Agenda Be in 2017?
**An FDAnews Webinar**
Dec. 15, 2016 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/newadministration    

On November 8 the United States elected Donald Trump. Come January, Republicans will control the White House, the Senate and the House of Representatives.

Change is coming.

What does this mean for the FDA and its regulated industries?

Steve Grossmann, a long-time D.C. insider, who served as a Senate Health Committee Staff Director and Deputy Assistant Secretary of Health, will discuss what the FDA is doing today and what it likely will be doing under the next administration.

After this 90-minute webinar attendees will learn:

  •     The likelihood that the current commissioner will continue to head the agency —for how long — and who the top candidates are to replace him
  •     Who will head the FDA transition team and how the process will likely unfold in the next months
  •     What the FDA’s likely priorities will be in 2017 under the new administration besides the medical device tax and drug pricing and the signals the industry needs to watch for to determine how the new policies will likely impact the industry
  •     How the new Congress is likely to impact what FDA does in 2017 and whether there will be increased monitoring of specific FDA projects, offices and policies

Register today for a glimpse of what 2017 will bring for the FDA and its regulated industries.

Meet the Presenter:
Steven Grossman, President, HPS Group, LLC

Steven Grossman is President of HPS Group, LLC, a consultancy that provides strategic counsel, analysis and advocacy on regulatory and policy issues involving the U.S. Food and Drug Administration. Mr. Grossman serves on the Board of Directors of the National Organization for Rare Disorders (NORD) and sits on the board’s executive committee. He is also a founder and deputy executive director of the Alliance for a Stronger FDA, a multi-stakeholder coalition that advocates for increased resources for the FDA. Earlier in his career, Mr. Grossman was Deputy Assistant Secretary for Health at HHS and Health Staff Director and Counsel to the Senate HELP Committee.

Who Will Benefit:
Anyone in a position to lead an FDA-regulated company, develops a new product for regulatory approval, or is concerned about trends in FDA regulation and policy will benefit from this webinar.

Webinar Details:
New Trump Administration, New Republican Congress:
What Will the FDA’s Agenda Be in 2017?
**An FDAnews Webinar**
Dec. 15, 2016 — 1:30 p.m. – 3:00 p.m. ET
http://www.fdanews.com/newadministration        

Tuition:
$287 per site

Easy Ways to Register:
Online:     http://www.fdanews.com/newadministration                            
By phone: 888-838-5578 or 703-538-7600

About FDAnews:
FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michelle Butler
FDANEWS
+1 (703) 538-7665
Email >
FDAnews
Like >
Visit website